MedTrace Logo

NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia

NCT00910741 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-01-09

No results posted yet for this study

Summary

The purpose of this study is to determine the recommended dose of NC-6004 according to the dose-limiting toxicity (DLT) in combination with Gemcitabine, and to assess the efficacy, safety and tolerability.

Conditions

  • Locally Advanced and Metastatic Pancreatic Cancer

Interventions

DRUG

Nanoplatin (NC-6004) and Gemcitabine

Sponsors & Collaborators

  • Orient Europharma Co., Ltd.

    collaborator INDUSTRY

  • NanoCarrier Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wu-Chou Su, MD · National Cheng-Kung University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Singapore
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00910741 on ClinicalTrials.gov